DAJY(002030)2024-04-29 09:07Financial Performance - The company's operating revenue for the reporting period was CNY 198,307,676.45, a decrease of 41.85% compared to the previous period[1]. - The net profit attributable to shareholders of the parent company was CNY -363,290,638.81, reflecting a decline of 1093.65% year-on-year due to fair value changes[3]. - The investment income for the period was CNY -22,096,061.02, a decrease of 68.59% due to losses from joint ventures[3]. - The company's net profit attributable to shareholders decreased to CNY 5,194,329,897.21 from CNY 5,557,620,536.02, a decrease of 6.5%[29]. - The net profit for the current period was CNY -361,140,883.90, compared to a net profit of CNY 37,777,912.70 in the previous period[35]. - The total comprehensive income for the current period was CNY -360,920,364.33, compared to CNY 37,408,320.51 in the previous period[37]. - Basic and diluted earnings per share were both CNY -0.2589, compared to CNY 0.0261 in the previous period[37]. Cash Flow and Assets - The cash flow from operating activities showed a net outflow of CNY -89,798,669.28, an improvement of 75.10% compared to the previous year[3]. - The cash inflow from operating activities was CNY 517,652,250.08, a decrease of 58.3% compared to CNY 1,241,998,318.39 in the previous period[40]. - The net cash outflow from operating activities was CNY -89,798,669.28, improving from CNY -360,633,771.25 in the previous period[40]. - The company's cash and cash equivalents decreased to CNY 798,472,734.66 from CNY 999,372,491.76, a decline of 20.1%[19]. - The total assets of the company decreased to CNY 10,374,456,579.57 from CNY 11,017,916,882.14, a decline of 5.8%[29]. - The total cash and cash equivalents at the end of Q1 2024 were ¥790,061,357.41, down from ¥989,274,472.71 at the beginning of the period[44]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 160,754, with the largest shareholder holding 16.63% of the shares[4]. - The top shareholder, Guangzhou Guangyong Technology Development Co., Ltd., holds 233,391,995 shares, accounting for approximately 16.83% of the total share capital[8]. - The second-largest shareholder, Guangzhou Biomedical and Health Industry Investment Co., Ltd., holds 140,344,607 shares, representing about 10.19% of the total share capital[8]. - The total number of shares involved in the securities lending business by the top 10 shareholders is 28,858,717 shares, which is approximately 2.06% of the total share capital[12]. - The company has reported changes in the top 10 shareholders due to securities lending activities, highlighting shareholder dynamics[13]. Operational Changes and Future Outlook - The company has obtained a medical device registration certificate, indicating progress in product development[14]. - The company announced a performance forecast for the year 2023, suggesting potential growth in revenue[16]. - The company has completed the registration change for its second-largest shareholder, indicating structural changes in ownership[16]. - The company plans to utilize idle self-owned funds for cash management, which may enhance financial flexibility[16]. - The company has received cash dividends from its wholly-owned subsidiary, reflecting positive cash flow management[16]. - The company is actively involved in the securities lending business, with significant shares lent out, indicating liquidity management strategies[12]. Cost Management - The company's sales expenses decreased by 52.19% to CNY 25,419,046.72, attributed to the reduction in operating revenue[1]. - Total operating costs for Q1 2024 were CNY 207,951,519.66, down from CNY 331,655,918.97, reflecting a reduction of 37.3%[29]. - Research and development expenses for Q1 2024 were CNY 56,401,238.80, down from CNY 76,407,740.73, a decrease of 26.2%[29].